IPO - IMMUNIC, INC.

Form Type: 424B5

Filing Date: 2025-05-30

Corporate Action: Ipo

Type: New

Accession Number: 000119380525000756

Filing Summary: Immunic, Inc. is offering pre-funded warrants to purchase 86,666,667 shares of its common stock, accompanied by Series A and Series B warrants for the same number of shares. The pre-funded warrants are priced at $0.7499 each and will bring total proceeds of approximately $64.99 million before expenses. The Series A warrants will expire on December 31, 2025, and have an exercise price of $0.75, while Series B warrants have the same exercise price and will expire five years from the issuance date. The common stock is listed on the Nasdaq under the symbol 'IMUX' and had a closing price of $0.91 on May 28, 2025. The document highlights the company's ongoing clinical programs and its classification as a smaller reporting company under U.S. federal securities laws, which allows for certain reductions in disclosure obligations. The underwriters expect to deliver the warrants to purchasers on June 3, 2025. Investing in these securities is noted as involving a high degree of risk, and the SEC has not assessed the accuracy or completeness of the supplement.

Form Type: 8-K

Filing Date: 2025-05-28

Corporate Action: Ipo

Type: New

Accession Number: 000119380525000730

Filing Summary: On May 28, 2025, Immunic, Inc. announced the commencement of an underwritten public offering of pre-funded warrants to purchase shares of its common stock, series A warrants, and series B warrants. These securities are linked to an effective registration statement previously filed on November 22, 2023, and declared effective by the SEC on May 31, 2024. The Company has issued a preliminary prospectus supplement for this offering on the same date. Additionally, the Company published an updated corporate presentation detailing extended data from its phase 2 CALLIPER trial of vidofludimus calcium, an investigational drug for chronic inflammatory and autoimmune diseases. The updated corporate presentation was made available on the Company’s website on the same day, May 28, 2025.